Brand Name
Lumerax DS Tablet (DS = Double Strength)
🔹 Composition
Each tablet contains:
-
Artemether 80 mg
-
Lumefantrine 480 mg
🔹 Manufacturer
Ipca Laboratories Ltd.
🔹 Category
Antimalarial Medicine
📌 Description
Lumerax DS Tablet is a double-strength Artemisinin Combination Therapy (ACT) containing Artemether (a fast-acting schizonticide) and Lumefantrine (a long-acting antimalarial). It is recommended for the treatment of acute, uncomplicated malaria caused by Plasmodium falciparum, including drug-resistant strains. Its dual action provides rapid parasite clearance and sustained protection against relapse.
✅ Indications / Uses
Lumerax DS Tablet is prescribed for:
-
Uncomplicated malaria caused by Plasmodium falciparum
-
Drug-resistant malaria (including chloroquine-resistant strains)
-
Mixed malaria infections (as per physician’s advice)
💊 Dosage & Administration
-
Adults & Children (>35 kg): 4 tablets per dose, twice daily for 3 days (total 6 doses).
-
Must be taken with milk or fatty meals to enhance absorption.
-
Always follow physician’s prescribed schedule.
-
Not recommended for infants under 5 kg or for malaria prevention.
⚠️ Side Effects
Common:
-
Headache, dizziness
-
Abdominal pain, nausea, vomiting
-
Loss of appetite, weakness
Serious (rare):
-
QT prolongation (irregular heartbeat)
-
Severe allergic reactions (rash, swelling, breathing difficulty)
-
Liver or blood-related disturbances
⚠️ Precautions & Warnings
-
Not to be used in severe malaria cases.
-
Caution in patients with heart disease, liver/kidney impairment.
-
Avoid concurrent QT-prolonging drugs.
-
Safe in pregnancy only if prescribed.
-
Breastfeeding women should consult doctor before use.
📦 Storage
-
Store below 25–30°C, in a dry place.
-
Protect from sunlight and moisture.
-
Keep out of reach of children.
🏷️ Key Highlights
-
Double-strength Artemisinin Combination Therapy
-
WHO-recommended for uncomplicated malaria
-
Effective against drug-resistant P. falciparum
-
Provides fast action & long-lasting protection
Reviews
There are no reviews yet.